Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.87 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.87 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.87 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.87 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.87 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.59 |
| ▸ | CNR1 | P21554 | 3/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24202345 | 1.00 | F2 (0.87) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL19705583 | 0.86 | PLCD1 (0.69) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL18779801 | 0.84 | TDP1 (0.78) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL24590149 | 0.84 | F2 (0.66) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL20006677 | 0.84 | TDP1 (0.71) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL22493325 | 0.84 | HLCS (0.71) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL15870672 | 0.84 | HLCS (0.71) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL2632289 | 0.84 | TDP1 (0.71) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL17881931 | 0.84 | TDP1 (0.71) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL12320610 | 0.84 | HLCS (0.71) | F2PRSS1PRSS2PRSS3TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024112581-A1 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR CONJUGATED BIOTIN | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2024-05-30 | — | — | WO | claimed |
| WO-2024038095-A1 | NOVEL ANTI-RGMb ANTIBODIES | IOME BIO (FR) | 2024-02-22 | — | — | WO | claimed |
| EP-3720959-B1 | SELECTING FOR DEVELOPABILITY OF POLYPEPTIDE DRUGS IN EUKARYOTIC CELL DISPLAY SYSTEMS | IONTAS LTD (GB) | 2026-05-06 | — | — | EP | disclosed |
| US-20260110690-A1 | PROBE AND METHODS FOR IDENTIFYING HOST CELL PROTEIN IMPURITIES | REGENERON PHARMACEUTICALS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-20260109758-A1 | RECOMBINANT BISPECIFIC ANTIBODIES TARGETING TSLP AND IL4R | BIOSION INC (CN) | 2026-04-23 | — | — | US | disclosed |
| EP-3707508-B1 | METHOD FOR DETECTION OF AN ANALYTE | FUND IMDEA NANOCIENCIA (ES) | 2026-04-15 | — | — | EP | disclosed |
| US-20260091108-A1 | ANTI-CCR8 ANTIBODIES AND USES THEREOF | VACCINEX, INC. (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260092121-A1 | ANTI-TRKB/CD3 ANTIBODIES AND USES THEREOF | TALEM THERAPEUTICS LLC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12570747-B2 | TGF-beta-RII binding proteins | MERUS N.V. (NL) | 2026-03-10 | — | — | US | disclosed |
| US-20260062471-A1 | ANTIBODY AND USE THEREOF | EARENDIL LABS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4694916-A1 | ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR ?? AGONISTS | SOTIO Biotech Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-3970743-A1 | BISPECIFIC ANTIBODY BINDING TO CD40 AND FAP | Kyowa Kirin Co., Ltd. (JP) | 2022-03-23 | — | — | EP | disclosed |
| WO-2022053839-A1 | SINGLE DOMAIN ANTIBODIES THAT TARGET SARS-COV-2 | THE ROSALIND FRANKLIN INSTITUTE (GB) | 2022-03-17 | — | — | WO | disclosed |
| CN-114181296-A | High-affinity fusion protein of PD-1 extracellular domain mutant and pharmaceutical composition and application thereof | 江苏东抗生物医药科技有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-11274153-B2 | Anti-PD-L1 nanobody and use thereof | INNOVENT BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2022-03-15 | — | — | US | disclosed |
| US-20220047714-A1 | COMPOSITIONS OF PROTEIN COMPLEXES AND METHODS OF USE THEREOF | GOOD THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220049007-A1 | ANTIBODY MOLECULES THAT BIND PD-L1 AND CD137 | F-Star Beta Limited (GB) | 2022-02-17 | — | — | US | disclosed |
| CN-114031682-A | High-affinity fusion protein of PD-1 extracellular domain mutant and pharmaceutical composition and application thereof | 江苏东抗生物医药科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20090208451-A1 | HALOGEN PHOSPHONATE MONOESTERS | INTEGRIGEN, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090208451-A1 | HALOGEN PHOSPHONATE MONOESTERS | INTEGRIGEN, INC. (US) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570747-B2 | TGF-beta-RII binding proteins | TGFBR2, TGFBR1, IGSF11 | F2 4106/4885PRSS1 3645/4885PRSS2 4342/4885 |
| US-20260062471-A1 | ANTIBODY AND USE THEREOF | TNFSF11, TNFRSF9, TNFRSF1A | F2 2211/4885PRSS1 2562/4885PRSS2 3042/4885 |
| US-20260109758-A1 | RECOMBINANT BISPECIFIC ANTIBODIES TARGETING TSLP AND IL4R | IL2RA, TSLP, IL2 | F2 3092/4885PRSS1 908/4885PRSS2 1041/4885 |
| US-20090208451-A1 | HALOGEN PHOSPHONATE MONOESTERS | FCGRT, PTMS, DNPEP | F2 1427/4885PRSS1 823/4885PRSS2 674/4885 |
| US-20260092121-A1 | ANTI-TRKB/CD3 ANTIBODIES AND USES THEREOF | NTRK1, NTRK2, CD2 | F2 4767/4885PRSS1 2944/4885PRSS2 2679/4885 |
| US-20260091108-A1 | ANTI-CCR8 ANTIBODIES AND USES THEREOF | VSIG8, CCR8, IGLV6-57 | F2 4829/4885PRSS1 3410/4885PRSS2 3828/4885 |
| US-20260110690-A1 | PROBE AND METHODS FOR IDENTIFYING HOST CELL PROTEIN IMPURITIES | BTD, LIPC, LPL | F2 3773/4885PRSS1 1418/4885PRSS2 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.